These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7795147)

  • 21. [Therapeutic use of hemoderivatives].
    Yurrebaso Eguilior N; Mota Villaplana FM; Montoro Ronsano JB
    Sangre (Barc); 1997 Oct; 42(5):423-7. PubMed ID: 9424747
    [No Abstract]   [Full Text] [Related]  

  • 22. Transposition of the Blood Directive into national law--the perspective of Portugal.
    Gonçalves MH; Muon MC; Gonçalves Jd
    Transfus Clin Biol; 2005 Feb; 12(1):18-20. PubMed ID: 15814287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The World Federation of Hemophilia's third global forum on the Safety and Supply of Hemophilia Treatment Products, 22-23 September 2003, Budapest, Hungary.
    Brooker M
    Haemophilia; 2004 May; 10(3):290-4. PubMed ID: 15086330
    [No Abstract]   [Full Text] [Related]  

  • 24. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease.
    Josephson CD; Abshire TC
    Best Pract Res Clin Haematol; 2006; 19(1):35-49. PubMed ID: 16377540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The regulation of medicinal products derived from human blood or plasma in the European Community.
    Brunko P
    Dev Biol Stand; 1993; 81():269-71. PubMed ID: 8174813
    [No Abstract]   [Full Text] [Related]  

  • 27. [Community requirements relating to drugs derived from human blood and plasma].
    Brunko P
    Ann Pharm Fr; 1994; 52(2):89-98. PubMed ID: 7944184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Understanding the role of the European public institutions in blood transfusion].
    Behr-Gross ME
    Transfus Clin Biol; 2009 May; 16(2):237-40. PubMed ID: 19443256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemophilia.
    Aledort LM
    N Engl J Med; 2001 Oct; 345(14):1066; author reply 1067. PubMed ID: 11586968
    [No Abstract]   [Full Text] [Related]  

  • 30. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework.
    Moltzan CJ; Anderson DA; Callum J; Fremes S; Hume H; Mazer CD; Poon MC; Rivard G; Rizoli S; Robinson S
    Transfus Med; 2008 Apr; 18(2):112-20. PubMed ID: 18399845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bleeding and clotting: new therapies and old issues revisited.
    Lee CA; Aledort LM
    Haemophilia; 2009 Mar; 15(2):592-6. PubMed ID: 19335754
    [No Abstract]   [Full Text] [Related]  

  • 32. The improved factor concentrate.
    Lillicrap D
    Hamostaseologie; 2009 Jan; 29(1):71-3. PubMed ID: 19151851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hemorrhagic congenital diseases: What can be the future of plasma-derived products against recombinants?].
    Schved JF
    Transfus Clin Biol; 2015 Aug; 22(3):85-9. PubMed ID: 25933512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Transfusion medicine in unified Europe. Brief report on the status of transfusion medicine in central and east European countries].
    Brüster HT; Lehnert E
    Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():16-8. PubMed ID: 7841775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chinese villages and their sustainable future: the European Union-China-Research Project "SUCCESS".
    Dumreicher H
    J Environ Manage; 2008 Apr; 87(2):204-15. PubMed ID: 17888563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of thromboelastographic patterns with clinical presentation and rationale for use of antifibrinolytics in severe haemophilia patients.
    Ghosh K; Shetty S; Kulkarni B
    Haemophilia; 2007 Nov; 13(6):734-9. PubMed ID: 17973850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New high-technology products for the treatment of haemophilia.
    Pipe SW; Saint-Remy JM; Walsh CE
    Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developing an administrative plan for transfusion medicine--a global perspective.
    Sullivan P
    Transfusion; 2005 Oct; 45(4 Suppl):224S-40S. PubMed ID: 16181405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should clinical freedom be constrained in the name of self-sufficiency?
    Schimpf K
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S47-9. PubMed ID: 7795139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The EEC and the regulation of blood derivatives.
    Horaud F
    Dev Biol Stand; 1993; 81():273-6. PubMed ID: 8174814
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.